Linezolid compared with teicoplanin for the treatment of suspected for proven Gram-positive infections

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 2, 2004, Pages 335-344

  Wilcox, Mark ^a   Nathwani, Dilip ^b   Dryden, Matthew ^c  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c ROYAL HAMPSHIRE COUNTY HOSPITAL   (United Kingdom)

Author keywords

Glycopeptide; Gram positive bacteria; Oxazolidinones

Indexed keywords

AMIKACIN; AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LINEZOLID; METRONIDAZOLE; TEICOPLANIN;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ADMINISTRATION ROUTE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERADICATION THERAPY; EXPERIENCE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HEMATOLOGIC DISEASE; HEMOLYSIS; HUMAN; INCIDENCE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MICROBIOLOGICAL EXAMINATION; MULTICENTER STUDY; NEUROLOGIC DISEASE; NONHUMAN; NUTRITIONAL DISORDER; OPEN STUDY; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN INFECTION; SKIN MANIFESTATION; SOFT TISSUE INFECTION; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ACETAMIDES; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; COSTS AND COST ANALYSIS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; TEICOPLANIN;

EID: 1242352622     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh088     Document Type: Article

References (36)

1. Reacher, M. H., Shah, A., Livermore, D. M. et al. (2000). Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. British Medical Journal 320, 213-6.
2. Murray, B. E. (2000). Vancomycin-resistant enterococcal infections. New England Journal of Medicine 342, 710-21.
3. Pallares, R., Dick, R., Wenzel, R. P. et al. (1993). Trends in antimicrobial utilization at a tertiary teaching hospital during a 15-year period (1978-1992). Infection Control and Hospital Epidemiology 14, 376-82.
4. Smith, T. L., Pearson, M. L., Wilcox, K. R. et al. (1999). Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. New England Journal of Medicine 340, 493-501.
5. Centers for Disease Control and Prevention. (2002). Staphylococcus aureus resistant to vancomycin - United States, 2002. Morbidity and Mortality Weekly Report 51, 565-7.
6. Centers for Disease Control and Prevention. (2002). Staphylococcus aureus resistant to vancomycin - PA, 2002. Morbidity and Mortality Weekly Report 51, 902.
7. Wood, M. J. (1996). The comparative efficacy and safety of teicoplanin and vancomycin. Journal of Antimicrobial Chemotherapy 37, 209-22.
8. Anonymous. (2000). MRSA with intermediate resistance to teicoplanin. Communicable Disease Report. CDR Weekly 10, 99-102.
9. Guerin, F., Buu-Hoi, A., Mainardi, J. L. et al. (2000). Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital. Journal of Clinical Microbiology 38, 2985-8.
10. MacKenzie, F. H., Greig, P., Morrison, D. et al. (2002). Identification and characterization of teicoplanin-intermediate Staphylococcus aureus blood culture isolates in NE Scotland. Journal of Antimicrobial Chemotherapy 50, 689-97.
11. Swaney, S. M., Aoki, H., Ganoza, M. C. et al. (1998). The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrobial Agents and Chemotherapy 42, 3251-5.
12. Zurenko, G. E., Gibson, J. K., Shinabarger, D. L. et al. (2001). Oxazolidinones: a new class of antibacterials. Current Opinion in Pharmacology 1, 470-6.
13. Rubinstein, E., Cammarata, S. K., Oliphant, T. H. et al. (2001). Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clinical Infectious Diseases 32, 402-12.
14. Stevens, D. L., Herr, D., Lampiris, H. et al. (2002). Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clinical Infectious Diseases 34, 1481-90.
15. Stevens, D. L., Smith, L. G., Bruss, J. B. et al. (2000). Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy 44, 3408-13.
16. Bone, R. C., Balk, R. A., Cerra, F. B. et al. (1992). Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101, 1644-55.
17. Blackwelder, W. C. (1982). Proving the null hypothesis in clinical trials. Controlled Clinical Trials 3, 345-53.
18. Makuch, R. & Simon, R. (1978). Sample size requirements for evaluating a conservative therapy. Cancer Treatment Reports 62, 1037-40.
19. Tam, V. H., Jumbe, N. L., Briceland, L. L. et al. (1995). A comparative study of vancomycin and β-lactams in the treatment of staphylococcal bacteraemia in hemodialysis patients. In Program and Abstracts of the Thirty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract 1095, p. 723. American Society for Microbiology, Washington, DC, USA.
20. Karchmer, A. W. (1991). Staphylococcus aureus and vancomycin: the sequel. Annals of Internal Medicine 115, 739-41.
21. Harding, I., McGowan, A. P., White, L. O. et al. (2000). Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentration and outcome. Journal of Antimicrobial Chemotherapy 45, 835-41.
22. Gilbert, D. N., Wood, C. A. & Kimbrough, R. C. (1991). Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon. Antimicrobial Agents and Chemotherapy 35, 79-87.
23. Wilson, A. P. R., Grunenberg, R. N. & Neu, H. (1993). Dosage recommendations for teicoplanin. Journal of Antimicrobial Chemotherapy 32, 792-6.
24. Khatib, R., Riederer, K. M., Held, M. et al. (1995). Protracted and recurrent methicillin-resistant Staphylococcus aureus bacteremia despite defervescence with vancomycin therapy. Scandinavian Journal of Infectious Diseases 27, 529-32.
25. Cremieux, A. C. & Carbon, C. (1992). Pharmacokinetic and pharmacodynamic dynamic requirements for antibiotic therapy of experimental endocarditis. Antimicrobial Agents and Chemotherapy 36, 2069-74.
26. Wilson, A. P. & Gaya, H. (1996). Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases. Journal of Antimicrobial Chemotherapy 38, 507-21.
27. Pea, F., Brollo, L., Viale, P. et al. (2003). Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. Journal of Antimicrobial Chemotherapy 51, 971-5.
28. Gonzalez, C., Gonzalez, C., Rubio, M. et al. (1999). Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clinical Infectious Diseases 29, 1171-7.
29. Burnie, J., Matthews, R., Jiman-Fatami, A. et al. (2000). Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin. Clinical Infectious Diseases 31, 684-9.
30. Faville, R. J., Zaske, D. E., Kaplan, E. L. et al. (1978). Staphylococcus aureus endocarditis. Combined therapy with vancomycin and rifampin. Journal of the American Medical Association 240, 1963-5.
31. Levine, D. P., Fromm, B. S. & Reddy, B. R. (1991). Response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Annals of Internal Medicine 115, 674-80.
32. Gerson, S. L., Kaplan, S. L., Bruss, J. B. et al. (2002). Hematologic effects of linezolid: summary of clinical experience. Antimicrobial Agents and Chemotherapy 46, 2723-6.
33. Orrick, J. J., Johns, T., Janelle, J. et al. (2002). Thrombocytopenia secondary to linezolid administration: what is the risk? Clinical Infectious Diseases 35, 348-9.
34. Wood, M. J. (2000). Comparative safety of teicoplanin and vancomycin. Journal of Chemotherapy 12, Suppl. 5, 21-5.
35. Li, J. Z., Willke, R. J., Rittenhouse, B. E. et al. (2002). Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections. Pharmacotherapy 22, 45S-54S.
36. Nathwani, D. (2001). Economic impact and formulary positioning of linezolid: a new anti-Gram-positive antimicrobial. Journal of Hospital Infection 49, Suppl. A, S33-41.